S D Quinn1, J Vedelago2, W Gedroyc3, L Regan4. 1. Department of Obstetrics and Gynaecology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. Electronic address: Stephen.quinn@imperial.nhs.uk. 2. Department of Radiology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. Electronic address: John_vedelago@yahoo.com. 3. Department of Radiology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. Electronic address: w.gedroyc@imperial.ac.uk. 4. Department of Obstetrics and Gynaecology, St. Mary's Hospital, Praed Street, London W2 1NY, United Kingdom. Electronic address: l.regan@imperial.ac.uk.
Abstract
OBJECTIVE: To examine the safety and re-intervention rates following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids at 5 years. To assess how the non-perfused volume (NPV), fibroid signal intensity and use of gonadotrophin-releasing hormone analogues (GnRHa) affect the re-intervention rates. STUDY DESIGN: Cohort study of women undergoing MRgFUS for treatment of their uterine fibroids between 2003 and 2010. RESULTS: Of 280 women undergoing MRgFUS the rate of minor complications was 3.9% and there were 3 serious complications (1.1%) including one skin burn, a fibroid expulsion and one case of persistent neuropathy. The NPVs achieved following MRgFUS have increased as the experience with this treatment has grown. In a 5-year follow-up study of 162 women, the overall re-intervention rate was 58.64%, but in those treatments with greater than 50% NPV the re-intervention rate was 50%. CONCLUSION: MRgFUS treatment of uterine fibroids is a safe treatment for uterine fibroids. The re-intervention rate at 5 years is high, but the improvements in NPVs achieved may further improve the long term results.
OBJECTIVE: To examine the safety and re-intervention rates following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids at 5 years. To assess how the non-perfused volume (NPV), fibroid signal intensity and use of gonadotrophin-releasing hormone analogues (GnRHa) affect the re-intervention rates. STUDY DESIGN: Cohort study of women undergoing MRgFUS for treatment of their uterine fibroids between 2003 and 2010. RESULTS: Of 280 women undergoing MRgFUS the rate of minor complications was 3.9% and there were 3 serious complications (1.1%) including one skin burn, a fibroid expulsion and one case of persistent neuropathy. The NPVs achieved following MRgFUS have increased as the experience with this treatment has grown. In a 5-year follow-up study of 162 women, the overall re-intervention rate was 58.64%, but in those treatments with greater than 50% NPV the re-intervention rate was 50%. CONCLUSION: MRgFUS treatment of uterine fibroids is a safe treatment for uterine fibroids. The re-intervention rate at 5 years is high, but the improvements in NPVs achieved may further improve the long term results.
Authors: Carlo Masciocchi; Francesco Arrigoni; Fabiana Ferrari; Aldo Victor Giordano; Sonia Iafrate; Ilaria Capretti; Ester Cannizzaro; Alfonso Reginelli; Anna Maria Ierardi; Chiara Floridi; Alessio Salvatore Angileri; Luca Brunese; Antonio Barile Journal: Med Oncol Date: 2017-02-24 Impact factor: 3.064